Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics Inc (NQ: STOK )

11.91 -0.46 (-3.72%)
Streaming Delayed Price Updated: 1:56 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 360,185
Open 12.16
Bid (Size) 11.89 (1)
Ask (Size) 11.92 (1)
Prev. Close 12.37
Today's Range 11.73 - 12.39
52wk Range 3.350 - 17.58
Shares Outstanding 44,188,534
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
From Stoke Therapeutics, Inc.
Via Business Wire

Performance

YTD
+103.24%
+103.24%
1 Month
-20.76%
-20.76%
3 Month
-7.17%
-7.17%
6 Month
-8.94%
-8.94%
1 Year
+222.76%
+222.76%

More News

Read More
A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics
Via Benzinga
Analyst Expectations For Stoke Therapeutics's Future
Via Benzinga
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
Via Benzinga
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
From Stoke Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
From Stoke Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
What's Going On With Stoke Therapeutics Stock Tuesday?
Via Benzinga
Stoke Therapeutics Announces Proposed Public Offering
From Stoke Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.